Division of Complex Drug Analysis and Division of Pharmaceutical Analysis, Office of Testing and Research, Office of Pharmaceutical Quality, Center for Drug Evaluation and Research, Food and Drug Administration, St Louis, Missouri.
Division of Applied Regulatory Science, Office of Clinical Pharmacology, Office of Translational Sciences, Center for Drug Evaluation and Research, Food and Drug Administration. Silver Spring, Maryland.
JAMA Netw Open. 2021 Jun 1;4(6):e2118253. doi: 10.1001/jamanetworkopen.2021.18253.
A publication reported that N-nitrosodimethylamine (NDMA), a probable human carcinogen, was formed when ranitidine and nitrite were added to simulated gastric fluid. However, the nitrite concentrations used were greater than the range detected in acidic gastric fluid in prior clinical studies.
To characterize NDMA formation following the addition of ranitidine to simulated gastric fluid using combinations of fluid volume, pH levels, and nitrite concentrations, including physiologic levels.
DESIGN, SETTING, AND PARTICIPANTS: One 150-mg ranitidine tablet was added to 50 or 250 mL of simulated gastric fluid with a range of nitrite concentrations from the upper range of physiologic (100 μmol/L) to higher concentrations (10 000 μmol/L) with a range of pH levels. NDMA amounts were assessed with a liquid chromatography-mass spectrometry method.
NDMA detected in simulated gastric fluid 2 hours after adding ranitidine.
At a supraphysiologic nitrite concentration (ie, 10 000 μmol/L), the mean (SD) amount of NDMA detected in 50 mL simulated gastric fluid 2 hours after adding ranitidine increased from 222 (12) ng at pH 5 to 11 822 (434) ng at pH 1.2. Subsequent experiments with 50 mL of simulated gastric fluid at pH 1.2 with no added nitrite detected a mean (SD) of 22 (2) ng of NDMA, which is the background amount present in the ranitidine tablets. Similarly, at the upper range of physiologic nitrite (ie, 100 μmol/L) or at nitrite concentrations as much as 50-fold greater (1000 or 5000 μmol/L) only background mean (SD) amounts of NDMA were observed (21 [3] ng, 24 [2] ng, or 24 [3] ng, respectively). With 250 mL of simulated gastric fluid, no NDMA was detected at the upper physiologic range (100 μmol/L) or 10-fold physiologic (1000 μmol/L) nitrite concentrations, while NDMA was detected (mean [SD] level, 7353 [183] ng) at a 50-fold physiologic nitrite concentration (5000 μmol/L).
In this in vitro study of ranitidine tablets added to simulated gastric fluid with different nitrite concentrations, ranitidine conversion to NDMA was not detected until nitrite was 5000 μmol/L, which is 50-fold greater than the upper range of physiologic gastric nitrite concentrations at acidic pH. These findings suggest that ranitidine is not converted to NDMA in gastric fluid at physiologic conditions.
有出版物报道,当雷尼替丁和亚硝酸盐被添加到模拟胃液中时,形成了 N-亚硝基二甲胺(NDMA),一种可能的人类致癌物。然而,使用的亚硝酸盐浓度大于先前临床研究中酸性胃液中检测到的范围。
使用不同的液体体积、pH 值和亚硝酸盐浓度(包括生理浓度)组合,描述雷尼替丁添加到模拟胃液中后 NDMA 的形成情况。
设计、设置和参与者:将一片 150 毫克雷尼替丁添加到 50 或 250 毫升模拟胃液中,亚硝酸盐浓度范围从生理范围(100 μmol/L)到较高浓度(10000 μmol/L),pH 值范围较广。使用液相色谱-质谱法评估 NDMA 含量。
添加雷尼替丁 2 小时后在模拟胃液中检测到的 NDMA。
在亚硝酸盐浓度高于生理水平(即 10000 μmol/L)时,添加雷尼替丁后 2 小时在 50 毫升模拟胃液中检测到的 NDMA 平均(SD)量从 pH 值为 5 时的 222(12)ng 增加到 pH 值为 1.2 时的 11822(434)ng。随后在 pH 值为 1.2 且没有添加亚硝酸盐的 50 毫升模拟胃液中的实验中,检测到的 NDMA 平均(SD)量为 22(2)ng,这是雷尼替丁片剂中存在的背景量。同样,在生理亚硝酸盐上限(即 100 μmol/L)或亚硝酸盐浓度高达 50 倍(1000 或 5000 μmol/L)时,仅观察到背景平均(SD)量的 NDMA(分别为 21[3]ng、24[2]ng 或 24[3]ng)。在 250 毫升模拟胃液中,在生理范围内(100 μmol/L)或生理范围内(1000 μmol/L)的 10 倍浓度下,均未检测到 NDMA,而在生理亚硝酸盐浓度(5000 μmol/L)下,检测到 NDMA(平均[SD]水平,7353[183]ng)。
在这项对添加不同亚硝酸盐浓度的模拟胃液中雷尼替丁片剂的体外研究中,仅在亚硝酸盐浓度为 5000 μmol/L 时才检测到雷尼替丁转化为 NDMA,这是酸性 pH 值下生理胃内亚硝酸盐浓度的 50 倍。这些发现表明,雷尼替丁在生理条件下不会在胃液中转化为 NDMA。